Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Recurrent Glioblastoma Multiforme Clinical Trial

Official title: A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Status Terminated

Clinical Trial Summary

This is a multicenter, open-label, Phase 1b/2 efficacy and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy (or futility) of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose (RP2D) identified in Phase 1 studies (7.5 mg/m2 Berubicin HCl), on the endpoint of ORR in up to approximately 61 patients. A central reader will determine the radiologic responses for each patient according to m RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline.

Clinical Trial Description

The planned minimum duration of the study for an individual patient is approximately 11 weeks as follows:

• A 4-week Screening Period

• A 3-week Treatment Period (ie, one 3 week treatment cycle)

• A 4-week End-of-Treatment follow-up Period after the last dose The 3-week treatment cycles may be repeated in the absence of clinical and/or neurological deterioration, or unacceptable toxicity, and as long as both the patient and investigator agree that further therapy is in the patient's best interest.

After the End-of-Treatment follow-up visit, patients will enter a Post-Study follow-Up Period of up to approximately 2 years. ;

Related Conditions & MeSH terms

• Glioblastoma
• Recurrence
• Recurrent Glioblastoma Multiforme

• NCT number: NCT04915404
• Study type: Interventional
• Source: WPD Pharmaceuticals Sp. z o.o.
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: December 7, 2022
• Completion date: December 30, 2023